UR-13870 is a p38 mitogen-activated protein kinase (MAPK) inhibitor potentially for the treatment of autoimmune disease and neuropathic pain. UR-13870 treatment significantly reduced OX-42, metabotropic glutamate type 5 receptor (mGluR5), and NMDA (N-methyl-d-aspartate) 2B subunit receptor (NR2B) expression in the anterior cingulate cortex after spinal cord injury. UR-13870 treatment significantly decreased hindlimb hyperreflexia to both mechanical and cold stimuli after spared nerve injury without loss of general motor function, in addition to a reduction in pain-related anxiety behavior at day 21 after spared nerve injury, accompanied by normalization of OX-42 immunoreactivity within the ipsilateral lumbar dorsal horn.
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4℃ for short term (days to weeks), or -20℃ for long term (months).
HS Tariff Code
2934.99.9001
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.